Boehringer Ingelheim to make detailed clinical trial data more widely available

In order to add to scientific and medical progress, family-owned German pharma major Boehringer Ingelheim is engaged in a program to make clinical study data and other clinical study related documents more widely accessible for approved products or after termination of a drug development program.

Clinical study reports and other clinical documents can be requested via the Boehringer Ingelheim website. This will also enable researchers to request access to de-identified patient level study data which form the basis of clinical trial findings.

Access to patient level data

Researchers will be granted access via a secure analysis environment after approval of his/her study proposal by an independent external review panel and based on a data sharing agreement. This agreement will include obligations such as the commitment to use the data only for the purpose of the study proposal, to not attempt to identify study participants, to not misuse the data, eg, for own commercial interests, and to be "transparent" regarding the planned analysis and disclosure of results.